Publications by authors named "B K Li"

29,246 Publications

Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.

N Engl J Med 2021 Sep 18. Epub 2021 Sep 18.

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York (B.T.L.); the Netherlands Cancer Institute, Amsterdam (E.F.S); the National Cancer Center Hospital, Tokyo (Y.G.), Kindai University Hospital, Osaka (K.N.), and the National Cancer Center East, Kashiwa (H.U.) - all in Japan; Centre Hospitalier Universitaire, Toulouse (J.M.), Centre Léon Bérard, Lyon (M.P.), and the Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif (D.P.) - all in France; Karmanos Cancer Institute, Detroit (M.N.); the University of California, San Diego, Moores Cancer Center, San Diego (L.B.); Moffitt Cancer Center, Tampa, FL (A.N.S.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); University of Colorado, Aurora (J.M.P.); Hospital Universitario 12 de Octubre, H12O-Centro Nacional de Investigaciones Oncológicas (CNIO) Lung Cancer Clinical Research Unit, and Complutense University, Madrid (L.P.-A.); Daiichi Sankyo, Basking Ridge, NJ (K.S., R.S., Y.C., S.A., P.V., J.S.); and Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston (P.A.J.).

Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in patients with -mutant NSCLC have not been investigated extensively.

Methods: We conducted a multicenter, international, phase 2 study in which trastuzumab deruxtecan (6.4 mg per kilogram of body weight) was administered to patients who had metastatic -mutant NSCLC that was refractory to standard treatment. The primary outcome was objective response as assessed by independent central review. Secondary outcomes included the duration of response, progression-free survival, overall survival, and safety. Biomarkers of HER2 alterations were assessed.

Results: A total of 91 patients were enrolled. The median duration of follow-up was 13.1 months (range, 0.7 to 29.1). Centrally confirmed objective response occurred in 55% of the patients (95% confidence interval [CI], 44 to 65). The median duration of response was 9.3 months (95% CI, 5.7 to 14.7). Median progression-free survival was 8.2 months (95% CI, 6.0 to 11.9), and median overall survival was 17.8 months (95% CI, 13.8 to 22.1). The safety profile was generally consistent with those from previous studies; grade 3 or higher drug-related adverse events occurred in 46% of patients, the most common event being neutropenia (in 19%). Adjudicated drug-related interstitial lung disease occurred in 26% of patients and resulted in death in 2 patients. Responses were observed across different mutation subtypes, as well as in patients with no detectable HER2 expression or amplification.

Conclusions: Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated -mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Lung01 ClinicalTrials.gov number, NCT03505710.).
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2112431DOI Listing
September 2021

MoC Electrocatalysts for Kinetically Boosting Polysulfide Conversion in Quasi-Solid-State Lithium-Sulfur Batteries.

ACS Appl Mater Interfaces 2021 Sep 17. Epub 2021 Sep 17.

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P. R. China.

Lithium-sulfur batteries (LSBs) suffer from sluggish reaction kinetics of sulfur-containing species and loss of soluble polysulfides (PSs) during cycling, especially in the case of liquid electrolytes. Here, we improve the kinetics of sulfur species by decorating MoC nanoparticles on carbon nanotubes (CNTs) as the host for sulfur active mass. In addition, by use of gel polymer electrolytes (GPEs) derived from in situ polymerization of 1,3-dioxolane (DOL) to mitigate the diffusion of PSs and improve the stability of Li stripping/plating. As a result, the sulfur cathodes are endowed with enhanced initial specific capacity and suppressed dissolution of sulfur species. The cells with CNT/MoC/S cathodes and GPE exhibit excellent electrochemical performance. The anodes cycled with GPE show remarkably enhanced lithium plating-stripping behavior. Benefitting from the synergistic effect, LSBs with higher energy density and improved durability are obtained, demonstrating a new approach for developing high-performance quasi-solid-state Li metal batteries.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.1c14629DOI Listing
September 2021

Neutrophil mediated postoperative photoimmunotherapy against melanoma skin cancer.

Nanoscale 2021 Sep 17;13(35):14825-14836. Epub 2021 Sep 17.

Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Science, Changchun, 130022, China.

Surgery is the primary treatment option for most melanoma; however, high tumor recurrence rate after surgical resection becomes the main cause of death in cancer patients. The development of efficient drug delivery nanosystems to inhibit postoperative tumor recurrence becomes very necessary. In the present study, IR780 molecules and TRP-2 peptide were encapsulated in the hydrophobic shell and hydrophilic interior of TAT peptide functionalized liposomes to form LipIT NPs, which were further internalized into neutrophils (NEs) to achieve LipIT/NEs. After being intravenously injected into postoperative B16F10-bearing mice, LipIT/NEs could actively migrate toward the inflamed residual tumor and release LipIT through neutrophil extracellular traps (NETs). Under NIR laser irradiation, the LipIT exhibited both photothermal and photodynamic effects to induce immunogenic cell death for maturation of DCs, and simultaneously, to release TRP-2 peptide as a melanoma associated antigen to further strengthen the maturation of DCs, both of which prompts the activation of T cells and induces potent immune responses. LipIT/NEs hold great potential for the inhibition of postoperative tumor recurrence.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1039/d1nr04002bDOI Listing
September 2021

Localized surface plasmon resonance for enhanced electrocatalysis.

Chem Soc Rev 2021 Sep 17. Epub 2021 Sep 17.

Department of Chemistry, Key Lab of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, Beijing 100084, China.

Electrocatalysis plays a vital role in energy conversion and storage in modern society. Localized surface plasmon resonance (LSPR) is a highly attractive approach to enhance the electrocatalytic activity and selectivity with solar energy. LSPR excitation can induce the transfer of hot electrons and holes, electromagnetic field enhancement, lattice heating, resonant energy transfer and scattering, in turn boosting a variety of electrocatalytic reactions. Although the LSPR-mediated electrocatalysis has been investigated, the underlying mechanism has not been well explained. Moreover, the efficiency is strongly dependent on the structure and composition of plasmonic metals. In this review, the currently proposed mechanisms for plasmon-mediated electrocatalysis are introduced and the preparation methods to design supported plasmonic nanostructures and related electrodes are summarized. In addition, we focus on the characterization strategies used for verifying and differentiating LSPR mechanisms involved at the electrochemical interface. Following that are highlights of representative examples of direct plasmonic metal-driven and indirect plasmon-enhanced electrocatalytic reactions. Finally, this review concludes with a discussion on the remaining challenges and future opportunities for coupling LSPR with electrocatalysis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1039/d1cs00237fDOI Listing
September 2021

Using a reactive emulsifier to construct simple and convenient nanocapsules loaded with lambda-cyhalothrin to achieve efficient foliar delivery and insecticidal synergies.

Nanoscale 2021 Sep 17. Epub 2021 Sep 17.

College of Plant Protection, Shandong Agricultural University, Tai'an, Shandong 271018, P. R. China.

Nanocapsules are a promising controlled release formulation for foliar pest control. However, the complicated process and high cost limit widespread use in agriculture, so a simpler and more convenient preparation system is urgently needed. Meanwhile, under complex field conditions, the advantageous mechanism of the nanosize effect and sustained release have no quantitative and detailed study. In this study, a reactive emulsifier (OP-10) is used to participate in the interfacial polymerization of the nanoemulsion, and polymer nanocapsules loaded with lambda-cyhalothrin ([email protected]) are quickly and easily prepared to study the efficacy and synergistic mechanism of foliar pest control. As a result, the nanocapsule is about 150 nm with a stable core-shell structure. The nanoscale state increases the distribution and adhesion of the particles on the leaf surface, which increases the contact efficiency of pesticides under the different physiological stages and behavioral activities of the target organism. The shell structure provides sustained release characteristics and increases the UV resistance by about 2.5 times for pesticides. Compared with microcapsules loaded with lambda-cyhalothrin ([email protected]), [email protected] not only shows rapid and synergistic insecticidal efficacy but also provides sustained insecticidal efficacy. The mortality of NCS is 3.4 times that of the nanosized emulsion in water (NEW) at the lowest concentration (0.5 mg L), and the control efficacy remained 77.3% after 7 days. Compared with NEW, [email protected] provides excellent field efficacy, while LC for zebrafish is only 0.68 times without increasing the aquatic toxicity risk.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1039/d1nr04381aDOI Listing
September 2021
-->